171 related articles for article (PubMed ID: 25331625)
1. A new reversible and potent P2Y12 receptor antagonist (ACT-246475): tolerability, pharmacokinetics, and pharmacodynamics in a first-in-man trial.
Baldoni D; Bruderer S; Krause A; Gutierrez M; Gueret P; Astruc B; Dingemanse J
Clin Drug Investig; 2014 Nov; 34(11):807-18. PubMed ID: 25331625
[TBL] [Abstract][Full Text] [Related]
2. Clinical Pharmacology of the Reversible and Potent P2Y
Juif PE; Boehler M; Dobrow M; Ufer M; Dingemanse J
J Clin Pharmacol; 2019 Jan; 59(1):123-130. PubMed ID: 30088663
[TBL] [Abstract][Full Text] [Related]
3. Effect of Rifampin-Mediated OATP1B1 and OATP1B3 Transporter Inhibition on the Pharmacokinetics of the P2Y12 Receptor Antagonist Selatogrel.
Schilling U; Dingemanse J; Voors-Pette C; Romeijn C; Dogterom P; Ufer M
Clin Transl Sci; 2020 Sep; 13(5):886-890. PubMed ID: 32166864
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics and tolerability of single and multiple doses of ticagrelor in healthy Chinese subjects: an open-label, sequential, two-cohort, single-centre study.
Li H; Butler K; Yang L; Yang Z; Teng R
Clin Drug Investig; 2012 Feb; 32(2):87-97. PubMed ID: 22168538
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics, pharmacodynamics, tolerability and safety of single ascending doses of ticagrelor, a reversibly binding oral P2Y(12) receptor antagonist, in healthy subjects.
Teng R; Butler K
Eur J Clin Pharmacol; 2010 May; 66(5):487-96. PubMed ID: 20091161
[TBL] [Abstract][Full Text] [Related]
6. Insights from In Vitro and Clinical Data to Guide Transition from the Novel P2Y12 Antagonist Selatogrel to Clopidogrel, Prasugrel, and Ticagrelor.
Schilling U; Dingemanse J; Dobrow M; Baumann M; Riederer MA; Juif PE; Ufer M
Thromb Haemost; 2021 Jun; 121(6):755-766. PubMed ID: 33412611
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetic and pharmacodynamic effects of elinogrel: results of the platelet function substudy from the intravenous and oral administration of elinogrel to evaluate tolerability and efficacy in nonurgent percutaneous coronary intervention patients (INNOVATE-PCI) trial.
Angiolillo DJ; Welsh RC; Trenk D; Neumann FJ; Conley PB; McClure MW; Stephens G; Kochman J; Jennings LK; Gurbel PA; Wójcik J; Dabrowski M; Saucedo JF; Stumpf J; Buerke M; Broderick S; Harrington RA; Rao SV
Circ Cardiovasc Interv; 2012 Jun; 5(3):347-56. PubMed ID: 22619259
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics, pharmacodynamics, and tolerability of single and multiple doses of ticagrelor in Japanese and Caucasian volunteers.
Teng R; Butler K
Int J Clin Pharmacol Ther; 2014 Jun; 52(6):478-91. PubMed ID: 24755129
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics, pharmacodynamics, safety and tolerability of multiple ascending doses of ticagrelor in healthy volunteers.
Butler K; Teng R
Br J Clin Pharmacol; 2010 Jul; 70(1):65-77. PubMed ID: 20642549
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics and pharmacodynamics of ticagrelor in subjects on hemodialysis and subjects with normal renal function.
Teng R; Muldowney S; Zhao Y; Berg JK; Lu J; Khan ND
Eur J Clin Pharmacol; 2018 Sep; 74(9):1141-1148. PubMed ID: 29850937
[TBL] [Abstract][Full Text] [Related]
11. Safety, Tolerability, and Pharmacodynamics of AZD3366 (Optimized Human CD39L3 Apyrase) Alone and in Combination With Ticagrelor and Acetylsalicylic Acid: A Phase 1, Randomized, Placebo-Controlled Study.
Kardassis D; Egnell AC; Åstrand M; Daniels SJ; Whatling C; Fjellström O; Gabrielsen A
J Am Heart Assoc; 2024 Jun; 13(11):e033985. PubMed ID: 38804212
[TBL] [Abstract][Full Text] [Related]
12. Morphine interaction with prasugrel: a double-blind, cross-over trial in healthy volunteers.
Hobl EL; Reiter B; Schoergenhofer C; Schwameis M; Derhaschnig U; Lang IM; Stimpfl T; Jilma B
Clin Res Cardiol; 2016 Apr; 105(4):349-55. PubMed ID: 26493304
[TBL] [Abstract][Full Text] [Related]
13. Transition from Syringe to Autoinjector Based on Bridging Pharmacokinetics and Pharmacodynamics of the P2Y
Zenklusen I; Hsin CH; Schilling U; Kankam M; Krause A; Ufer M; Dingemanse J
Clin Pharmacokinet; 2022 May; 61(5):687-695. PubMed ID: 34961905
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics, pharmacodynamics, and safety of ticagrelor in volunteers with mild hepatic impairment.
Butler K; Teng R
J Clin Pharmacol; 2011 Jul; 51(7):978-87. PubMed ID: 20926753
[TBL] [Abstract][Full Text] [Related]
15. SAR216471, an alternative to the use of currently available P2Y₁₂ receptor inhibitors?
Delesque-Touchard N; Pflieger AM; Bonnet-Lignon S; Millet L; Salel V; Boldron C; Lassalle G; Herbert JM; Savi P; Bono F
Thromb Res; 2014 Sep; 134(3):693-703. PubMed ID: 25064036
[TBL] [Abstract][Full Text] [Related]
16. Comparative bioavailability study of triflusal oral solution vs. triflusal capsules in healthy subjects. A single, randomized, two-way cross-over, open-label phase I study.
Izquierdo I; Borja J; Rovira S; Pelagio P; Torres F; Cebrecos J; García-Rafanell J
Arzneimittelforschung; 2010; 60(1):36-41. PubMed ID: 20184225
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics and pharmacodynamics of single and multiple doses of prasugrel in healthy native Chinese subjects.
Cui YM; Wang ZN; Chen XW; Zhang HL; Zhao X; Zhou Y
Acta Pharmacol Sin; 2012 Nov; 33(11):1395-400. PubMed ID: 23085738
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics, bioequivalence, tolerability, and effects on platelet counts of two formulations of anagrelide in healthy volunteers and patients with thrombocythemia associated with chronic myeloproliferation.
Petrides PE; Gisslinger H; Steurer M; Linkesch W; Krumpl G; Schüller A; Widmann R
Clin Ther; 2009 Feb; 31(2):386-98. PubMed ID: 19302911
[TBL] [Abstract][Full Text] [Related]
19. A randomized, double-blind, active-controlled phase 2 trial to evaluate a novel selective and reversible intravenous and oral P2Y12 inhibitor elinogrel versus clopidogrel in patients undergoing nonurgent percutaneous coronary intervention: the INNOVATE-PCI trial.
Welsh RC; Rao SV; Zeymer U; Thompson VP; Huber K; Kochman J; McClure MW; Gretler DD; Bhatt DL; Gibson CM; Angiolillo DJ; Gurbel PA; Berdan LG; Paynter G; Leonardi S; Madan M; French WJ; Harrington RA;
Circ Cardiovasc Interv; 2012 Jun; 5(3):336-46. PubMed ID: 22647518
[TBL] [Abstract][Full Text] [Related]
20. Intravenous Clopidogrel (MDCO-157) Compared with Oral Clopidogrel: The Randomized Cross-Over AMPHORE Study.
Collet JP; Funck-Brentano C; Prats J; Salem JE; Hulot JS; Guilloux E; Hu MY; He K; Silvain J; Gallois V; Brugier D; Anzaha G; Galier S; Nicolas N; Montalescot G
Am J Cardiovasc Drugs; 2016 Feb; 16(1):43-53. PubMed ID: 26386578
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
